文献速递消化系统肿瘤

非酒精性脂肪性肝病相关肝细胞癌的临床特征、监测、治疗分配和结局:系统综述与Meta分析

Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.
PubMed 文献 · Lancet Oncol · 2022-03-04

该系统综述与Meta分析纳入61项研究共94,636例患者,比较非酒精性脂肪性肝病(NAFLD)相关肝细胞癌与其他原因肝细胞癌的临床特征与结局。NAFLD相关肝细胞癌占15.1%(95%CI 11.9-18.9),患者更常无肝硬化(38.5% vs 14.6%),接受监测比例更低(32.8% vs 55.7%),总生存无差异(HR 1.05,95%CI 0.92-1.20),无病生存更长(HR 0.79,95%CI 0.63-0.99)。

要点

  • NAFLD相关肝细胞癌占全部肝细胞癌的15.1%(95%CI 11.9-18.9)。
  • NAFLD相关肝细胞癌患者更常无肝硬化(38.5% vs 14.6%),接受监测比例更低(32.8% vs 55.7%)。
  • 两组总生存无显著差异(HR 1.05,95%CI 0.92-1.20),NAFLD相关组无病生存更长(HR 0.79,95%CI 0.63-0.99)。

核心结论

  • NAFLD相关肝细胞癌与其他原因肝细胞癌相比,无肝硬化患者比例更高、监测率更低。
  • 作者建议应为无肝硬化但肝细胞癌高风险NAFLD患者制定监测策略。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE和Embase自建库至2022年1月17日的英文文献。
  • 纳入横断面和纵向观察性研究,排除儿科研究,最终纳入61项研究(1980年1月至2021年5月进行),共94,636例患者。

主要发现

  • NAFLD相关肝细胞癌占15.1%(95%CI 11.9-18.9)。
  • NAFLD相关肝细胞癌患者较其他原因肝细胞癌患者年龄更大(p<0.0001)、BMI更高(p<0.0001),更常合并代谢性疾病(糖尿病p<0.0001、高血压p<0.0001、高脂血症p<0.0001)或心血管疾病(p=0.0055)。
  • NAFLD相关肝细胞癌患者无肝硬化比例更高(38.5%,95%CI 27.9-50.2 vs 其他原因肝细胞癌14.6%,95%CI 8.7-23.4;p<0.0001)。
  • NAFLD相关肝细胞癌患者肿瘤直径更大(p=0.0087),更常为单结节病变(p=0.0003),但BCLC分期、TNM分期、甲胎蛋白浓度和ECOG体能状态与其他原因肝细胞癌相似。
  • NAFLD相关肝细胞癌患者接受监测比例更低(32.8%,95%CI 12.0-63.7 vs 其他原因肝细胞癌55.7%,95%CI 24.0-83.3;p<0.0001)。

关键数值与推荐

  • NAFLD相关肝细胞癌与其他原因肝细胞癌在治疗分配(治愈性治疗、姑息性治疗和最佳支持治疗)方面无显著差异。
  • 两组总生存无显著差异(HR 1.05,95%CI 0.92-1.20,p=0.43)。
  • NAFLD相关肝细胞癌患者无病生存更长(HR 0.79,95%CI 0.63-0.99,p=0.044)。

临床怎么用

  • 作者建议应为无肝硬化但肝细胞癌高风险的NAFLD患者制定监测策略。

局限性

  • 大多数分析存在显著异质性(I²>75%)。
  • 所有文章存在低至中等偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical presentation and outcomes of non-alcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma are unclear when compared with hepatocellular carcinoma due to other causes. We aimed to establish the prevalence, clinical features, surveillance rates, treatment allocation, and outcomes of NAFLD-related hepatocellular carcinoma. METHODS: In this systematic review and meta-analysis, we searched MEDLINE and Embase from inception until Jan 17, 2022, for articles in English that compared clinical features, and outcomes of NAFLD-related hepatocellular carcinoma versus hepatocellular carcinoma due to other causes. We included cross-sectional and longitudinal observational studies and excluded paediatric studies. Study-level data were extracted from the published reports. The primary outcomes were (1) the proportion of hepatocellular carcinoma secondary to NAFLD, (2) comparison of patient and tumour characteristics of NAFLD-related hepatocellular carcinoma versus other causes, and (3) comparison of surveillance, treatment allocation, and overall and disease-free survival outcomes of NAFLD-related versus non-NAFLD-related hepatocellular carcinoma. We analysed proportional data using a generalised linear mixed model. Pairwise meta-analysis was done to obtain odds ratio (OR) or mean difference, comparing NAFLD-related with non-NAFLD-related hepatocellular carcinoma. We evaluated survival outcomes using pooled analysis of hazard ratios. FINDINGS: Of 3631 records identified, 61 studies (done between January, 1980, and May, 2021; 94 636 patients) met inclusion criteria. Overall, the proportion of hepatocellular carcinoma cases secondary to NAFLD was 15·1% (95% CI 11·9-18·9). Patients with NAFLD-related hepatocellular carcinoma were older (p<0·0001), had higher BMI (p<0·0001), and were more likely to present with metabolic comorbidities (diabetes [p<0·0001], hypertension [p<0·0001], and hyperlipidaemia [p<0·0001]) or cardiovascular disease at presentation (p=0·0055) than patients with hepatocellular carcinoma due to other causes. They were also more likely to be non-cirrhotic (38·5%, 27·9-50·2 vs 14·6%, 8·7-23·4 for hepatocellular carcinoma due to other causes; p<0·0001). Patients with NAFLD-related hepatocellular carcinoma had larger tumour diameters (p=0·0087), were more likely to have uninodular lesions (p=0·0003), and had similar odds of Barcelona Clinic Liver Cancer stages, TNM stages, alpha fetoprotein concentration, and Eastern Cooperative Oncology Group (ECOG) performance status to patients with non-NAFLD-related hepatocellular carcinoma. A lower proportion of patients with NAFLD-related hepatocellular carcinoma underwent surveillance (32·8%, 12·0-63·7) than did patients with hepatocellular carcinoma due to other causes (55·7%, 24·0-83·3; p<0·0001). There were no significant differences in treatment allocation (curative therapy, palliative therapy, and best supportive care) between patients with NAFLD-related hepatocellular carcinoma and those with hepatocellular carcinoma due to other causes. Overall survival did not differ between the two groups (hazard ratio 1·05, 95% CI 0·92-1·20, p=0·43), but disease-free survival was longer for patients with NAFLD-related hepatocellular carcinoma (0·79, 0·63-0·99; p=0·044). There was substantial heterogeneity in most analyses (I2>75%), and all articles had low-to-moderate risk of bias. INTERPRETATION: NAFLD-related hepatocellular carcinoma is associated with a higher proportion of patients without cirrhosis and lower surveillance rates than hepatocellular carcinoma due to other causes. Surveillance strategies should be developed for patients with NAFLD without cirrhosis who are at high risk of developing hepatocellular carcinoma. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022. PMID: 35255263. doi:10.1016/S1470-2045(22)00078-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。